Patients with high-risk neuroblastoma who were treated with ch14.18 in combination with IL-2 and GM-CSF with indication that the chemokine CXCL9 was somewhat prognostic at pretreatment, suggesting recruitment of immune effector cells like NK cells to the tumor could be beneficial [135]. Here, IL2 is linked to neuroblastoma.